Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 23, Issue 12, 2011, Pages 1105-1110

  Hod, K ^a   Dickman, R ^b   Sperber, A ^c   Melamed, S ^d   Dekel, R ^c   Ron, Y ^c   Halpern, Z ^c   Berliner, S ^c   Maharshak, N ^c  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d ACADEMIC COLLEGE OF TEL AVIV YAFFO   (Israel)

Author keywords

High sensitivity C reactive protein; Irritable bowel syndrome; Low grade inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; INFLAMMATION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; ROC CURVE;

EID: 81855194450     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01788.x     Document Type: Article

References (34)

1. Drossman DA, Li Z, Toner BB et al. Functional bowel disorders. A multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 986-95.
2. Sperber AD, Carmel S, Atzmon Y et al. Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol 2000; 95: 995-8.
3. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20(Suppl. 2): 1-9.
4. Chan J, Gonsalkorale WM, Perrey C et al. IL-10 and TGF-B genotypes in irritable bowel syndrome: evidence to support an inflammatory component. Gastroenterol 2000;118(4 pt 1):A184.
5. Saito YA, Talley NJ. Genetics of irritable bowel syndrome. Am J Gastroenterol 2008; 103: 2100-4. quiz 5.
6. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-6.
7. Spiller RC. Irritable bowel syndrome: bacteria and inflammation-clinical relevance now. Curr Treat Options Gastroenterol 2007; 10: 312-21.
8. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
9. Barbara G, Corinaldesi R. Probiotics: could they turn out to be ineffective in irritable bowel syndrome? Dig Liver Dis 2000; 32: 302-4.
10. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352: 1187-9.
11. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut 2002; 51(Suppl. 1): i41-4.
12. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
13. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3.
14. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
15. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
16. Maharshak N, Zilberman L, Arbel Y et al. Microinflammation in patients with Crohn's disease in clinical remission. J Crohns Colitis 2008; 2: 310-4.
17. Wilson PW. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation 2004; 110: e568-71.
18. Devaraj S, O'Keefe G, Jialal I. Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005; 90: 4549-54.
19. Steinvil A, Shirom A, Melamed S et al. Relation of educational level to inflammation-sensitive biomarker level. Am J Cardiol 2008; 102: 1034-9.
20. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
21. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008; 79(Suppl. 8): 1544-51.
22. Elsenbruch S, Orr WC. Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol 2001; 96: 460-6.
23. Kasim-Karakas SE, Tsodikov A, Singh U, Jialal I. Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am J Clin Nutr 2006; 83: 774-9.
24. Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: the ATTICA study. Am J Clin Nutr 2004; 80: 862-7.
25. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-41.
26. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
27. Park CS, Ihm SH, Yoo KD et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. Am J Cardiol 2010; 105: 1284-8.
28. Poullis AP, Zar S, Sundaram KK et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409-12.
29. Roka R, Rosztoczy A, Leveque M et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 550-5.
30. Simren M, Mansson A, Langkilde AM et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 108-15.
31. Ringel Y, Sperber AD, Drossman DA. Irritable bowel syndrome. Annu Rev Med 2001; 52: 319-38.
32. Sperber AD, Shvartzman P, Friger M, Fich A. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? Eur J Gastroenterol Hepatol 2007; 19: 441-7.
33. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691-9.
34. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-42.